Expertise in
6
conditions

Alain P. Gadisseur

Edegem, VLG, BE 
Expertise in
6
conditions
Edegem, VLG, BE 

Overview

Alain Gadisseur practices practicing medicine in Edegem, Belgium.

Mr. Gadisseur is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Von Willebrand Disease (VWD), Febrile Neutropenia, Wilms Tumor, Blood Clots, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 44 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Edegem, VLG 2650, Belgium
Other Locations
Antwerpen, VLG, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase II Study Evaluating the Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk Diffuse Large B-cell Lymphoma
A Phase II Study Evaluating the Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk Diffuse Large B-cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: January 05, 2026
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Enrollment Status: Terminated
Publish Date: October 20, 2025
Intervention Type: Drug
Study Drugs: Itacitinib, Methylprednisolone, Prednisone
Study Phase: Phase 2/Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: March 02, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Enrollment Status: Completed
Publish Date: November 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

44 Total Publications

Temporal changes of the von Willebrand factor-ADAMTS13 axis during the first 24 hours in major trauma patients with isolated brain injury and without brain injury: a prospective observational study.
Temporal changes of the von Willebrand factor-ADAMTS13 axis during the first 24 hours in major trauma patients with isolated brain injury and without brain injury: a prospective observational study.
Journal: Shock (Augusta, Ga.)
Published: July 04, 2026

Frequently Asked Questions about Alain P. Gadisseur

Is Alain P. Gadisseur a top-rated expert for Von Willebrand Disease (VWD)?

MediFind is an objective health platform that identifies experts based on real-world data. Alain P. Gadisseur is classified as an Distinguished expert for Von Willebrand Disease (VWD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Alain P. Gadisseur participate in research or clinical trials?

Yes. Alain P. Gadisseur has published 44 articles and abstracts on conditions like Von Willebrand Disease (VWD). You can view a list of Alain P. Gadisseur's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Gadisseur's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile